NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Stock
NASDAQ · NAMS
22.85
Fundamentals
Market cap
$2.70B
Price / Earnings ratio
-9.1x
Price / Sales ratio
334.5x
Price / Book ratio
3.8x
Return on assets
-27.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NeutralNAMSAugust 5, 2026
MarketBeatNeutral
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NeutralNAMSAugust 5, 2026
Zacks Investment ResearchNeutral
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMS

MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NeutralNAMSMay 8, 2026
MarketBeatNeutral
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NeutralNAMSMay 7, 2026
Zacks Investment ResearchNeutral
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
32M21M10M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
923M609M305M0
Revenue to Profit
2025$26.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-203.8M
Net incomeEarnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NeutralNAMSAugust 5, 2026
MarketBeatNeutral
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NeutralNAMSAugust 5, 2026
Zacks Investment ResearchNeutral
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMS

MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NeutralNAMSMay 8, 2026
MarketBeatNeutral
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NeutralNAMSMay 7, 2026
Zacks Investment ResearchNeutral
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS

InvestorPlace
3 Drug Stocks to Watch as Alzheimer's Clinical Trials End
NeutralNAMSFebruary 24, 2023
InvestorPlaceNeutral
3 Drug Stocks to Watch as Alzheimer's Clinical Trials End
NAMS
About NewAmsterdam Pharma Company N.V. Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees100
CEODr. Michael Harvey Davidson FACC, Facp., M.D.
IPO DateNov 23, 2022
HeadquartersNaarden, Netherlands
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 1956 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 1974 |
| Mr. Robert W. Gunning C.P.A., CGMA | Principal Accounting Officer, VP & Controller | 1971 |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations | — |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 1976 |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations | — |
| Ms. Maryellen McQuade | Chief People Officer | — |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | 1987 |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | 1967 |
Fundamentals
Valuation
Market cap$2.70B
Price-to-sales ratio334.46
Price-to-book value3.77
Price-earnings ratio-9.10
Return on Equity-30.00%
Return on Sales-943.00%
Return on Assets-27.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.47
Income Statement
Average volume1,741,437
EBITDA$-242.58M
1 year high (52w)$42.21
1 year low (52w)$21.02
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$51.00
Est return
126.06%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -21.7 | +23.2 | ||||||||||
| 2023 | +19.5 | +2.9 | +2.2 | +5.2 | -5.5 | -13.8 | -4.0 | -8.8 | -11.3 | +6.9 | +5.4 | +15.3 |
| 2024 | +71.3 | +9.8 | +0.5 | +2.1 | -14.7 | +1.5 | -16.8 | -4.9 | +4.3 | -1.6 | +11.4 | +30.9 |
| 2025 | -14.1 | -1.7 | +1.0 | +4.1 | -9.6 | -4.3 | +19.7 | +13.0 | +15.5 | +29.3 | +11.6 | -11.4 |
| 2026 | -11.6 | +12.3 | -2.5 | -13.0 | +18.5 | +6.6 | -21.0 | -7.8 | -9.4 |



